SOURCES SOUGHT
A -- Resynthesis of Therapeutic Agents for Treatment of Infectious Diseases
- Notice Date
- 4/7/2003
- Notice Type
- Sources Sought
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700 B Rockledge Room 2230 MSC7612, Bethesda, MD, 20892-7605
- ZIP Code
- 20892-7605
- Solicitation Number
- N01-AI-05402
- Archive Date
- 6/6/2003
- Point of Contact
- Dominic Reeves, Contract Specialist, Phone 301-496-0612, Fax 301-402-0972, - Barbara Shadrick, Senior Contracting Officer, Phone 301-496-7288, Fax 301-480-5253,
- E-Mail Address
-
DReeves@niaid.nih.gov, bs92y@nih.gov
- Small Business Set-Aside
- Total Small Business
- Description
- The Division of AIDS (DAIDS) and the Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), intends to negotiate with Starks Associates for a modification of its contract No. N01-AI-05402, that was awarded as a 100% small business set-aside, under SIC 8731; NAICS 541710; size standard of 500 employees. This contract provides support to NIAID?s research to identify therapeutic agents for the prevention and treatment of infections with the human immunodeficiency virus (HIV), various opportunistic infections (OI?s) associated with acquired immunodeficiency syndrome (AIDS), and with Mycobacterium tuberculosis. Lead compounds are identified through individual research grants as well as DAIDS-sponsored programs such as the Integrated Preclinical/Clinical Program for novel HIV therapies and the National Cooperative Drug Discovery Groups for AIDS-associated OIs. Researchers in these and other DAIDS-sponsored pre-clinical programs are activity engaged in investigating the basic biology of the targeted pathogens, identifying novel therapeutic approaches to treat diseases caused by these infectious agents, and testing therapeutic strategies in vitro and in animal models. This contract provides resynthesis of potential therapeutic agents for treatment of infectious diseases. The planned negotiated modification will provide for a level of increased effort over a period of four (4) years (within the contract?s current period) in order to: (1) develop prodrug for cidofovir and to perform other antiviral synthesis, (2) increase the synthesis of the number of potential anti-infective agents of diverse classes of organic and organometallic compounds and (3) to fulfill an urgent need for synthesis of biodefense reagents. This will be for immediate use in a variety of preclinical and clinical drug development projects by investigators supported by the DMID. This activity will require expansion of all aspects of the contractor?s infrastructure, already in place, to meet this requirement for rapid response to the immediate and intensified synthesis demands of the Institute. Authority: 41 USC 253(c)(1), as set for in FAR 6.302-1(a)(2)(ii). Inherent duplication of cost to the Government and unacceptable delays in completing the project make competition unfeasible for this requirement. If there are responsible sources who feel that they are able to perform the requirement, they must respond by the closing date noted above. See Government-Wide Numbered Note 22. No collect calls will be accepted.
- Place of Performance
- Address: Continental United States
- Country: USA
- Country: USA
- Record
- SN00297302-W 20030409/030407213350 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |